PMID- 34181716
OWN - NLM
STAT- MEDLINE
DCOM- 20220329
LR  - 20240403
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Print)
IS  - 1058-4838 (Linking)
VI  - 74
IP  - 6
DP  - 2022 Mar 23
TI  - Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and 
      Meta-analysis of Randomized Controlled Trials.
PG  - 1022-1029
LID - 10.1093/cid/ciab591 [doi]
LID - ciab591
AB  - BACKGROUND: We systematically assessed benefits and harms of the use of 
      ivermectin (IVM) in patients with coronavirus disease 2019 (COVID-19). METHODS: 
      Published and preprint randomized controlled trials (RCTs) assessing the effects 
      of IVM on adult patients with COVID-19 were searched until 22 March 2021 in 5 
      engines. Primary outcomes were all-cause mortality rate, length of hospital stay 
      (LOS), and adverse events (AEs). Secondary outcomes included viral clearance and 
      severe AEs (SAEs). The risk of bias (RoB) was evaluated using the Cochrane Risk 
      of Bias 2.0 tool. Inverse variance random effect meta-analyses were performed, 
      with quality of evidence (QoE) evaluated using GRADE methods. RESULTS: Ten RCTs 
      (n = 1173) were included. The controls were the standard of care in 5 RCTs and 
      placebo in 5. COVID-19 disease severity was mild in 8 RCTs, moderate in 1, and 
      mild and moderate in 1. IVM did not reduce all-cause mortality rates compared 
      with controls (relative risk [RR], 0.37 [95% confidence interval, .12-1.13]; very 
      low QoE) or LOS compared with controls (mean difference, 0.72 days [95% 
      confidence interval, -.86 to 2.29 days]; very low QoE). AEs, SAEs, and viral 
      clearance were similar between IVM and control groups (low QoE for all outcomes). 
      Subgroups by severity of COVID-19 or RoB were mostly consistent with main 
      analyses; all-cause mortality rates in 3 RCTs at high RoB were reduced with IVM. 
      CONCLUSIONS: Compared with the standard of care or placebo, IVM did not reduce 
      all-cause mortality, LOS, or viral clearance in RCTs in patients with mostly mild 
      COVID-19. IVM did not have an effect on AEs or SAEs and is not a viable option to 
      treat patients with COVID-19.
CI  - (c) The Author(s) 2021. Published by Oxford University Press for the Infectious 
      Diseases Society of America. All rights reserved. For permissions, e-mail: 
      journals.permissions@oup.com.
FAU - Roman, Yuani M
AU  - Roman YM
AD  - Health Outcomes, Policy, and Evidence Synthesis (HOPES) Group, University of 
      Connecticut School of Pharmacy, Storrs, Connecticut, USA.
FAU - Burela, Paula Alejandra
AU  - Burela PA
AD  - Universidad Cientifica del Sur, Lima, Peru.
AD  - Centro de Investigacion, Instituto Peruano de Oncologia y Radioterapia, San 
      Isidro, Lima, Peru.
FAU - Pasupuleti, Vinay
AU  - Pasupuleti V
AD  - Cello Health, Yardley, Pennsylvania, USA.
FAU - Piscoya, Alejandro
AU  - Piscoya A
AD  - Unidad de Revisiones Sistematicas y Meta-analisis, Guias de Practica Clinica y 
      Evaluaciones de Tecnologias Sanitarias (URSIGET), Vicerrectorado de 
      Investigacion, Universidad San Ignacio de Loyola, La Molina, Lima, Peru.
FAU - Vidal, Jose E
AU  - Vidal JE
AD  - Division of Infectious Diseases, Hospital das Clinicas, Faculdade de Medicina da 
      Universidade de Sao Paulo, Sao Paulo, Brazil.
AD  - Department of Neurology, Instituto de Infectologia Emilio Ribas, Sao Paulo, 
      Brazil.
AD  - Laboratory of Medical Investigation, Unit 49, Hospital das Clinicas, Universidade 
      de Sao Paulo, Sao Paulo, Brazil.
FAU - Hernandez, Adrian V
AU  - Hernandez AV
AD  - Health Outcomes, Policy, and Evidence Synthesis (HOPES) Group, University of 
      Connecticut School of Pharmacy, Storrs, Connecticut, USA.
AD  - Unidad de Revisiones Sistematicas y Meta-analisis, Guias de Practica Clinica y 
      Evaluaciones de Tecnologias Sanitarias (URSIGET), Vicerrectorado de 
      Investigacion, Universidad San Ignacio de Loyola, La Molina, Lima, Peru.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases 
      Society of America
JID - 9203213
RN  - 70288-86-7 (Ivermectin)
SB  - IM
CIN - Clin Infect Dis. 2022 Mar 23;74(6):1122-1123. PMID: 34358293
MH  - Adult
MH  - Humans
MH  - Immunization, Passive/adverse effects/methods
MH  - Ivermectin/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Respiration, Artificial
MH  - *COVID-19 Drug Treatment
PMC - PMC8394824
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - ivermectin
OT  - meta-analysis
OT  - mortality
EDAT- 2021/06/29 06:00
MHDA- 2022/03/30 06:00
PMCR- 2021/06/28
CRDT- 2021/06/28 17:21
PHST- 2021/05/27 00:00 [received]
PHST- 2021/06/29 06:00 [pubmed]
PHST- 2022/03/30 06:00 [medline]
PHST- 2021/06/28 17:21 [entrez]
PHST- 2021/06/28 00:00 [pmc-release]
AID - 6310839 [pii]
AID - ciab591 [pii]
AID - 10.1093/cid/ciab591 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2022 Mar 23;74(6):1022-1029. doi: 10.1093/cid/ciab591.